NCT05949125
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05949125
Title Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) (RevSTAR-123)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AvenCell Europe GmbH
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | DEU


No variant requirements are available.